Articles

Thank you to reviewers

Published on 02 October 2019

Thank you to reviewers 2018

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal...

1.925 views

Read more →

Published on 27 October 2020

2020/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2020, Issue 3, 2020, Issue 3 Commentary Quality standards for biopharmaceuticals: the importance of good manufacturing practice Original Research Qualitative survey-based evaluation...

2.187 views

Read more →

Thank you to reviewers

Published on 30 May 2016

Thank you to reviewers 2015

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI...

2.426 views

Read more →

Published on 31 October 2016

2016/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2016, Issue 3 Letters to the Editor Is the EU ready for non-biological complex drug products? Commentary Biosimilars: achieving long-term savings and...

2.533 views

Read more →

Thank you to reviewers

Published on 24 March 2020

Thank you to reviewers 2019

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI...

2.375 views

Read more →

Published on 22 October 2014

2014/1 GaBI Journal Table of Contents

Contents Editor's Letter Editor’s introduction to the initial issue of the third volume of GaBI Journal Editorial Drug shortages hit US oncologists hard Letters to the Editor Common or distinct...

3.389 views

Read more →

Published on 16 April 2015

2015/1 GaBI Journal Table of Contents

Contents Editor’s Letter Editor’s introduction to the initial issue of the fourth volume of GaBI Journal Editorial Biosimilars: patient and physician acceptability is the fifth hurdle to market competition Letters...

3.256 views

Read more →

Published on 27 September 2017

2017/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2017, Issue 3 Commentary Patent expiry and costs for anti­cancer medicines for clinical use Original Research A survey of Australian prescribers’ views...

2.563 views

Read more →

Thank you to reviewers

Published on 29 November 2022

Thank you to reviewers 2021

The editors and publisher wish to express their gratitude to the colleagues listed below for their valuable contribution to the peer review process for the Generics and Biosimilars Initiative Journal (GaBI...

801 views

Read more →

Published on 07 January 2019

2018/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2018, Issue 3 Commentary Medicines regulation in the MENA region and the importance of the World Health Organization’s INN proposal of Biological...

2.266 views

Read more →

Published on 08 June 2016

2016/1 GaBI Journal Table of Contents

Contents Editor’s Letter Editor’s introduction to the initial issue of the fifth volume of GaBI Journal Letters to the Editor First biosimilar of infliximab approved in Brazil: response from the...

2.850 views

Read more →

Published on 24 March 2020

2020/1 GaBI Journal Table of Contents

Contents Editor’s Letter Editor’s introduction to the initial issue of the ninth volume of GaBI Journal Original Research Stability of the trastuzumab biosimilar ABP 980 compared to reference product after...

2.117 views

Read more →